Protocol Ledger

NCT05652894 · Phase III · ACTIVE NOT RECRUITING

A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer

Interventional Phase III clinical trial protocol NCT05652894 sponsored by Taizhou Hanzhong biomedical co in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-02-28 Enrollment: 190 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05652894
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)190 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05652894
Protocol FieldVerified Registry Value
NCT IdentifierNCT05652894
Consolidated Lead SponsorTaizhou Hanzhong biomedical co
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment190 participants (ESTIMATED)
Registered Start Date2023-02-28
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI